Emulating control arms for oncology clinical trials using real-world data

Trial data was used from published control arm results from 15 trials that supported drug approvals from January 1, 2016, to April 30, 2018 RWD cohorts were constructed using a nationwide EHR-derived de-identified database by aligning eligibility criteria and weighting to trial baseline characteristics The trial data and RWD cohorts were compared using Kaplan–Meier and…

Read More

75% ORR in maintenance therapy in multiple myeloma patients

Patients with MM have a median survival of at least 10 years, and despite improvements in prognosis, almost all patients will eventually relapse Ixazomib is an oral proteasome inhibitor (PI) approved for patients who have received at least 1 previous therapy for MM A total of 71 patients with newly diagnosed MM were observed after…

Read More

First treatment for sickle cell disease in over 20 years gets NICE recommendation

Eligible patients in England and Wales will soon have access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA) to treat vaso-occlusive crises (VOCs) By adopting a collaborative approach – including collecting prospective real-world data via the National Haemoglobinopathy Register (NHR) – this decision clears the way for patients with SCD in England to be…

Read More